Table 1.
Basic characteristics of the patients
| Characteristic | n (%) |
|---|---|
| Median age, years | 50 (21–83) |
| < 40 years | 55 (18.2%) |
| 40–49 years | 92 (30.5%) |
| 50–59 years | 90 (29.8%) |
| ≥ 60 years | 65 (21.5%) |
| Menopausal status | |
| Premenopausal | 157 (52.0%) |
| Postmenopausal | 145 (48.0%) |
| Type of histology | |
| Invasive ductal | 264 (87.4%) |
| Invasive lobular | 18 (6.0%) |
| Mixed | 11 (3.6%) |
| Others | 9 (3.0%) |
| Grade of histology | |
| I | 13 (4.3%) |
| II | 110 (36.4%) |
| III | 152 (50.3%) |
| Unknown | 27 (8.9%) |
| Tumor size | |
| I | 23 (7.6%) |
| II | 145 (48.0%) |
| III | 121 (40.1%) |
| IV | 13 (4.3%) |
| ER status | |
| Positive | 218 (72.2%) |
| Negative | 84 (27.8%) |
| PgR status | |
| Positive | 183 (60.6%) |
| Negative | 119 (39.4%) |
| HER2 status | |
| Positive | 122 (40.4%) |
| Negative | 180 (59.6%) |
| Subgroups | |
| HR+/HER2- | 151 (50.0%) |
| HR+/HER2+ | 80 (26.5%) |
| HR–/HER2+ | 42 (13.9%) |
| TN | 29 (9.6%) |
| Metastatic lymph nodes | 15 (10–53) |
| 10–15 | 159 (52.6%) |
| » 16 | 143 (47.4%) |
| Dissected lymph nodes | 23 (10–60) |
| Lymph node ratio, median (range) | 0.75 (0.18–1.0) |
| ≤ 0.75 | 157 (52.0%) |
| » 0.75 | 145 (48.0%) |
ER = estrogen receptor, PgR = progesterone receptor,
HER2 = human epithelial growth factor receptor 2,
HR = hormone receptor, TN = triple negative.